Plain-English translation of NCT06757647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication designed to treat chronic lymphocytic leukemia and small lymphocytic lymphoma (types of blood cancer). You would be eligible if you were previously taking a similar drug called ibrutinib but had to stop because it caused heart rhythm problems. The study will follow your heart health closely with imaging and blood tests while you take this medication over time.
Some patients with blood cancer cannot tolerate ibrutinib because it can cause dangerous heart rhythm problems. Researchers want to know if treats the cancer just as well while being gentler on the heart.
You likely qualify if…
You likely don't qualify if…
You would take tablets by mouth twice a day in 28-day cycles for as long as the medication is working and you tolerate it well. You would have regular clinic visits for heart imaging scans (MRI and CT), blood draws, and possibly bone marrow biopsies to check how your cancer is responding. After you finish taking the medication, you would be followed for up to 10 years with check-ins every 6 months to monitor your long-term heart health and cancer status.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States